Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula.
Publication/Presentation Date
5-1-2020
Abstract
BACKGROUND: A randomized controlled trial (RCT) of routine administration of pasireotide demonstrated decreased incidence of clinically significant postoperative pancreatic fistula (POPF). Recent studies have not replicated these results. A meta-analysis was performed to evaluate its efficacy in this setting.
METHODS: Prospective trials utilizing pasireotide prophylactically after pancreatectomy were reviewed. The primary outcome was clinically significant POPF. Secondary outcomes included length of stay (LOS), readmission rates, and mortality. Study heterogeneity was assessed.
RESULTS: Five studies totaling 1571 patients were identified. There was no difference in age, sex, or cancer rates. Pasireotide patients had smaller pancreatic ducts (
CONCLUSIONS: Routine administration of pasireotide did not decrease POPF rates for all pancreatectomies, but was associated with lower rates for PD and decreased readmission rates. Further prospective, randomized studies are warranted.
Volume
86
Issue
5
First Page
429
Last Page
436
ISSN
1555-9823
Published In/Presented At
Dalton, E. C., Johns, M. S., Rhodes, L., Merritt, W. T., Petrelli, N. J., & Tiesi, G. G. (2020). Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula. The American surgeon, 86(5), 429–436. https://doi.org/10.1177/0003134820918260
Disciplines
Medicine and Health Sciences
PubMedID
32684027
Department(s)
Department of Surgery
Document Type
Article